NCT00159432View on ClinicalTrials.gov

Study of Oxaliplatin, Capecitabine and Bevacizumab as First Line Treatment for Patients With Advanced Colorectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

June 30, 2009

Study Completion Date

March 31, 2013

Conditions
Colorectal Cancer
Interventions
DRUG

Oxaliplatin

DRUG

Bevacizumab

DRUG

Capecitabine

Trial Locations (1)

90033

U.S.C./Norris Comprehensive Cancer Center, Los Angeles

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Hoffmann-La Roche

INDUSTRY

collaborator

Genentech, Inc.

INDUSTRY

lead

University of Southern California

OTHER

NCT00159432 - Study of Oxaliplatin, Capecitabine and Bevacizumab as First Line Treatment for Patients With Advanced Colorectal Cancer | Biotech Hunter | Biotech Hunter